InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.09
(
0.08%
)
Bitcoin
63,135.99
(
-0.06%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 122991

Thursday, 07/07/2011 6:04:49 PM

Thursday, July 07, 2011 6:04:49 PM

Post# of 252311

VRUS—my hunch is the FDA is not that open-minded...

Well, well...I was able to nudge you off the fence :- )

I’m inclined to agree—i.e. I do not expect VRUS to submit an NDA in genotype-2/3 based on only the phase-2 data. However, oc631 has called everything correctly in the HCV arena to date, and he thinks this might be doable; for this reason alone, we should not dismiss the idea out of hand.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up